KaydedilenlerDerginizi ekleyin

Dergiler / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 1

Renal dysfunction as a marker of increased mortality in patients with pulmonary thromboembolism(Author`s Reply)

Anca OUATU
Mariana FLORİA
Catalina Arsenescu GEORGESCU
Sayfa
70–71
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

OUATU, A., FLORİA, M., GEORGESCU, C. A. (2016). Renal dysfunction as a marker of increased mortality in patients with pulmonary thromboembolism(Author`s Reply). The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 1, 70–71. https://ajindex.com/articles/365500

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. Nistor DO, Sîrbu V, Oltean G, Opriş M. Renal dysfunction as a mark-er of increased mortality in patients with pulmonary thrombembo-lism. Anatol J Cardiol 2016; 16: 00-00
  2. Ouatu A, Tãnase DM, Floria M, Ionescu SD, Ambãruş V, Arsenescu- Georgescu C. Chronic kidney disease: Prognostic marker of nonfa-tal pulmonary thromboembolism. Anatol J Cardiol 2015; 15: 938-43
  3. Sun Y, Wang Y, Jiang J, Wang L, Hu D. Renal dysfunction, CHADS2 score, and adherence to the anticoagulant treatment in nonvalvu-lar atrial fibrillation: A cross-sectional study in Mainland China. Clin Appl Thromb Hemost 2015 Oct 14. Epub of ahead of print
  4. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic em-bolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antago-nism for prevention of stroke and Embolism Trial in Atrial Fibrilla-tion) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrilla-tion) study cohorts. Circulation 2013; 127: 224-32.